Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson
Rhea-AI Filing Summary
Bicara Therapeutics Inc. reported that its Chief Financial Officer, Jennifer Larson, received a grant of 285,000 stock options on August 12, 2026. The options have an exercise price of $24.63 per share and are exercisable for an equal number of shares of common stock until August 12, 2036. According to the vesting terms, 25% of the options vest and become exercisable on August 12, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to her continued service. Following this award, she holds 285,000 derivative securities of this type directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Larson Jennifer
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 285,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 285,000 shares (Direct)
Footnotes (1)
- F1. 25% of the shares subject to this option vest and become exercisable on August 12, 2027, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Stock options granted: 285,000 options
Exercise price: $24.63 per share
Expiration date: August 12, 2036
+3 more
6 metrics
Stock options granted
285,000 options
Grant of stock options to CFO on August 12, 2026
Exercise price
$24.63 per share
Exercise price of the CFO’s stock option grant
Expiration date
August 12, 2036
Expiration of the granted stock options
Initial vesting tranche
25% on August 12, 2027
First vesting date and portion of options
Remaining vesting schedule
12 equal quarterly installments
Remainder of options vesting after August 12, 2027
Post-grant holdings
285,000 derivative securities
Total stock options of this type held directly after grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, quarterly installments
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 24.6300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to this option vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
quarterly installments financial
"remainder vesting in twelve equal quarterly installments"
FAQ
What did Bicara Therapeutics (BCAX) disclose about Jennifer Larson’s recent equity award?
Bicara Therapeutics disclosed that CFO Jennifer Larson received a grant of 285,000 stock options on August 12, 2026, giving her the right to buy an equal number of common shares at $24.63 per share, subject to vesting and expiration terms.
What is the exercise price of the new stock options granted to the BCAX CFO?
The stock options granted to the BCAX CFO have an exercise price of $24.63 per share. This is the price at which she can purchase common stock upon exercise, once the options have vested and before they expire on August 12, 2036.
How do the 285,000 BCAX stock options granted to the CFO vest over time?
The 285,000 BCAX stock options vest as follows: 25% vest on August 12, 2027, and the remaining 75% vest in twelve equal quarterly installments thereafter, contingent on Jennifer Larson’s continued service on each vesting date.
When do the newly granted BCAX stock options to the CFO expire?
The newly granted BCAX stock options to the CFO expire on August 12, 2036. She may exercise vested options at the $24.63 exercise price any time after vesting and before this expiration date, subject to plan terms.
How many BCAX derivative securities does the CFO hold after this stock option grant?
After this grant, the CFO holds 285,000 derivative securities of this stock option type directly. Each option represents the right to acquire one share of Bicara Therapeutics common stock, subject to the specified vesting schedule and expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
